Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
rXEb2qmP7DdSXLPu
Écouter
